Centessa Pharmaceuticals
CNTA
CNTA was delisted on the 23rd of June, 2026.
44 hedge funds and large institutions have $233M invested in Centessa Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 14 increasing their positions, 9 reducing their positions, and 3 closing their positions.
56% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 9
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
0% more funds holding
Funds holding: 44 → 44 (0)
8.53% less ownership
Funds ownership: 76.12% → 67.59% (-8.5%)
19% less capital invested
Capital invested by funds: $289M → $233M (-$55.5M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $3K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$7.4M |
| 2 |
TWM
Tanager Wealth Management
Goring On Thames,
United Kingdom
|
+$6.96M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.94M |
| 4 |
Morgan Stanley
New York
|
+$1.11M |
| 5 |
AAA
Affinity Asset Advisors
New York
|
+$807K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$5.23M |
| 2 |
Janus Henderson Group
London,
|
-$3.08M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
-$1.61M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$567K |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$218K |
CNTA Hedge Fund Activity: Q4 2022 in Review
44 of the 6,239 institutional investors tracked by Wall St. Rank reported a position in Centessa Pharmaceuticals (CNTA) for Q4 2022, worth a combined $233M — down 19% from $289M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new CNTA positions and 3 closed out — a net gain of 1 holder — while 14 added to existing stakes and 9 trimmed.
The largest buyer was EcoR1 Capital, adding an estimated $7.4M. The largest seller was Cormorant Asset Management, cutting an estimated $5.23M.
- 44 institutional investors held Centessa Pharmaceuticals (CNTA) as of Q4 2022, unchanged from Q3 2022.
- Funds reported $233M of Centessa Pharmaceuticals stock for Q4 2022, down 19% quarter-over-quarter.
- 4 funds opened new Centessa Pharmaceuticals positions in Q4 2022 and 3 closed out, a net change of +1 holder.
- The largest Centessa Pharmaceuticals buyer in Q4 2022 was EcoR1 Capital, an estimated $7.4M added.
- The largest Centessa Pharmaceuticals seller in Q4 2022 was Cormorant Asset Management, an estimated $5.23M sold.
Based on aggregated 13F filings for Q4 2022.